

# *SCOTT ALAN WEST, M.D.*

---

## **PRESIDENT / CEO CLINICAL NEUROSCIENCE SOLUTIONS, INC.**

### **CONTACT INFORMATION**

CNS Healthcare  
6750 Turkey Lake Road, 3<sup>rd</sup> Floor  
Orlando, FL 32819  
scott@cnshealthcare.com  
407/903-1680 (phone)  
407/903-1578 (fax)  
EIN: 59-3602109

#### **Affiliation**

#### **Investigator**

Clinical Neuroscience Solutions, Inc.  
207 West Gore Street, Suite 200, Orlando, FL 32806  
1997- Present

### **EDUCATION**

1982-1986    B.S., Florida State University  
                  Department of Biological Sciences  
                  Tallahassee, Florida

1986-1990    M.D., University of Florida College of Medicine  
                  Gainesville, Florida  
                  (P.I.M.S. 1986-1987)

### **PROFESSIONAL TRAINING**

1990-1991    Internship, Emory University School of Medicine, Atlanta, Georgia

1991-1993    Residency, Emory University School of Medicine, Department of  
                  Psychiatry, Atlanta, Georgia

1993-1994    Residency, University of Cincinnati College of Medicine, Department  
                  of Psychiatry, Cincinnati, OH

## **SCOTT ALAN WEST, M.D.**

---

- 1994-1995 Fellowship, Child and Adolescent Psychopharmacology, University of Cincinnati College of Medicine, Department of Psychiatry, Division of Child and Adolescent Psychiatry
- 1993-1995 Fellowship, Biological Psychiatry Program, University of Cincinnati College of Medicine, Department of Psychiatry, Cincinnati, OH

### **CLINICAL TRIALS EXPERIENCE**

- 1990 - Principal Investigator and Sub-Investigator, *extensive* experience in phase II – IV clinical research in children and adults. Diagnoses include ADHD, Alzheimer’s disease, bipolar disorders, dementias, depressive disorders, generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, schizoaffective disorder, schizophrenia, social phobia, Tourette’s syndrome.

Industry contracts history include: Abbott Laboratories, AstraZeneca, Bioavail Laboratories, Bristol-Myers Squibb, Celgene, Celltech, Cephalon, Eli Lilly, Forest, GlaxoSmithKline, Hoechst Marion Roussel, Janssen, McNeill, Merck, Mitsubishi, Novartis, Organon, Otsuka, Pfizer, RW Johnson, SmithKline Beecham, Sanofi, Shire, Solvay, Wyeth-Ayerst

### **PHARMACEUTICAL ADVISORY & CONSULTING EXPERIENCE**

- |          |             |          |                  |
|----------|-------------|----------|------------------|
| • Abbott | • Eli Lilly | • Otsuka | • PRI/RW Johnson |
| • Alza   | • Novartis  | • Pfizer | • Wyeth-Ayerst   |

### **LICENSURE (ACTIVE)**

Florida; May 31, 1995 - Present, No. ME 0068464

### **HOSPITAL APPOINTMENTS**

- OH 1993-1994 Clinical Fellow, Psychobiology Unit, University Hospital, Cincinnati, OH
- 1994-1995 Attending Physician, Psychobiology Unit, University Hospital, Cincinnati, OH

## **SCOTT ALAN WEST, M.D.**

---

- 1993-1995     Consultant, Kettering Medical Center, Kettering, OH
- 1994-1995     Director, Division of Child and Adolescent Psychopharmacology,  
Biological Psychiatry Program, University of Cincinnati College of  
Medicine, Cincinnati, OH
- 1994-1995     Consultant, Jewish Hospital, Cincinnati, OH
- 1995-1996     Medical Director, Affective Disorders Unit, Center for Psychiatry,  
Florida Hospital, Orlando, FL
- 1995-1998     Medical Staff, Florida Hospital, Orlando, FL
- 1996-1999     Medical Staff, University Behavioral Center, Orlando, FL
- 1996-1999     Medical Staff, Lakewood Adult Care Center, Orlando, FL
- 1997-1999     Medical Staff, Charter Behavioral Health System, Orlando, FL
- 1997-1998     Medical Director, Charter Behavioral Health System, Orlando, FL

### **ACADEMIC APPOINTMENTS**

- 1986-1987     Admissions Committee, University of Florida College of Medicine
- 1993-1995     Clinical Research Fellow, Biological Psychiatry Program, Department of  
Psychiatry, University of Cincinnati College of Medicine, Cincinnati,  
OH
- 1994-1995     Clinical Research Fellow, Child and Adolescent Psychopharmacology,  
Division of Child and Adolescent Psychiatry, Department of Psychiatry,  
University of Cincinnati College of Medicine, Cincinnati, OH
- 1994-1995     Volunteer Instructor in Psychiatry, University of Cincinnati College of  
Medicine, Cincinnati, OH Medicine, Cincinnati, OH
- 1994-1995     Medical Student Education Committee, Department of Psychiatry,  
University of Cincinnati College of Medicine
- 1994-1995     Clinical Biennium Curriculum Committee, University of Cincinnati  
College of Medicine

## **SCOTT ALAN WEST, M.D.**

---

1994-1995	Clinical Promotion Board, University of Cincinnati College of Medicine
1994-1995	Director, Medical Student Clerkship, Department Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH
1995-1998	Research Associate, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH
2003 -2005	Clinical Assistant Professor, Florida State University College of Medicine, Orlando Campus

### **PROFESSIONAL HONORS**

1990	Alpha Omega Alpha-Walt Oppelt Memorial Award, Excellence in Pharmacology and Therapeutics, University of Florida College of Medicine, Gainesville, FL
1992	Outstanding Resident Teacher Award, Emory University School of Medicine, Atlanta, GA
1994	Fellow, New Clinical Drug Evaluation Unit (NCDEU) Annual Conference, National Institute of Mental Health
1994	Jefferson Journal Award, Jefferson Journal of Psychiatry
1995	Lilly Fellowship Award, Society of Biological Psychiatry
1995	Roerig-Pfizer Golden Apple Award, University of Cincinnati College of Medicine
1996	Outstanding Clinician, Florida Hospital Center for Psychiatry

### **PROFESSIONAL ORGANIZATIONS**

- American Psychiatric Association
- American Academy of Pharmaceutical Physicians
- Florida Psychiatric Society

## **SCOTT ALAN WEST, M.D.**

---

### **TEACHING EXPERIENCE**

- 1984-1986 Teaching Assistant in Organic Chemistry, Florida State University, Tallahassee, Florida
- 1989-1990 Teaching Assistant for Clinical Clerkships, University of Florida College of Medicine, Gainesville, FL
- 1992-1993 Director of Clozapine Support and Education Group, Emory University School of Medicine, Grady Memorial Hospital, Atlanta, GA
- 1993-1994 Instructor for The Medical Interview Course, University of Cincinnati College of Medicine
- 1993-1994 Psychopharmacology Consultant and Lecturer, Department of Psychiatry, Kettering Medical Center, Kettering, OH
- 1993-1994 Lecturer and Supervisor for Psychiatry Clerkship, Jewish Hospital, University of Cincinnati College of Medicine
- 1993-1994 Lecturer, Introduction to Psychiatry, University of Cincinnati College of Medicine
- 1994-1995 Course Director, Medical Student Clerkship, Department of Psychiatry, University of Cincinnati College of Medicine
- 1994-1995 Lecturer, Advanced Psychopharmacology Resident Seminar, University of Cincinnati College of Medicine
- 1994-1995 Lecturer and Director, Medical Student Clerkship Psychopharmacology Series, University of Cincinnati College of Medicine
- 1996- Lecturer, CNS Healthcare
- 2003- 2005 Clinical Assistant Professor, Department of Clinical Sciences, Florida State University College of Medicine

### **BIBLIOGRAPHY**

#### ***Original Articles***

1. West SA: Medical education and the role of computers – as seen through the eyes of a

## SCOTT ALAN WEST, M.D.

---

- medical student. *J Med Systems* 1989;13(5):237-241.
2. **West SA**: Pharmacologic advances in the treatment of schizophrenia. *Jefferson J Psychiatry* 1993;11(2):8-17.
  3. Keck PE, McElroy SL, Strakowski SM, and **West SA**: Pharmacologic treatment of schizoaffective disorder. *Psychopharmacol* 1994;114:529-538.
  4. **West SA**, Keck PE, McElroy SL, Strakowski SM, Minnery KL, McConville BJ, Sorter MT: Open trial of valproate in the treatment of adolescent mania. *J Child Adol Psychopharmacol* 1994;4:263-267.
  5. Strakowski SM, McElroy SL, Keck PE, Jr, **West SA**: The co-occurrence of mania with medical and other psychiatric disorders. *Internat J Psychiatry Med* 1994; 24:305-328.
  6. **West SA**, McElroy SL, Strakowski SM, Keck PE, Jr, McConville BJ: Attention deficit hyperactivity disorder in adolescent mania. *Am J Psychiatry* 1995; 152:271-273.
  7. Tabb SE, **West SA**: The forgotten evaluation: taking competence seriously. *Jefferson J Psychiatry* 1995;12:47-52.
  8. Strakowski SM, Keck PE, Jr, McElroy SL, Lonczak HS, **West SA**: Chronology of comorbid and principal syndromes in first-episode psychosis. *Compr Psychiatry* 1995;36:106-112.
  9. Sax KW, Strakowski SM, McElroy SL, Keck PE, Jr, **West SA**: Attention and formal thought disorder in mixed and pure mania. *Biol Psychiatry* 1995;37:420-423.
  10. Strakowski SM, Lonczak HS, Sax KW, **West SA**, Crist A, Mehta R, Thienhaus OJ: The effects of race on diagnosis and disposition from a psychiatric emergency service. *J Clin Psychiatry* 1995;56:101-107.
  11. McElroy SL, Strakowski SM, Keck PE, Tugrul KL, **West SA**, Lonczak HS: Differences and similarities in mixed versus pure mania. *Compr Psychiatry* 1995; 36:187-194.
  12. **West SA**, Strakowski SM, Sax KW, Minnery KL, McElroy SL, Keck PE: The comorbidity of attention-deficit hyperactivity disorder in adolescent mania: potential diagnostic and treatment implications. *Psychopharmacol Bull* 1995;31:347-351.
  13. Keck PE, Jr, McElroy SL, Strakowski SM, **West SA**, Hawkins JM, Huber TJ, Newman RM: Outcome and comorbidity in first-compared with multiple-episode mania. *J Nerv Ment Dis* 1995;183:320-324.

## SCOTT ALAN WEST, M.D.

---

14. **West SA**, Keck PE, McElroy SL: Oral valproate loading in the treatment of adolescents with mixed bipolar disorder. *J Child Adol Psychopharmacol* 1995; 5:215-221.
15. Minnery KL, **West SA**, McConville BJ, Sorter MT: Setraline-induced mania in an adolescent. *J Child Adol Psychopharmacol* 1995;5:151-153.
16. Whittier MC, **West SA**, Galli VB, Raute NJ: Valproic acid for dysphoric mania and mental retardation in an adolescent. *J Clin Psychiatry* 1995;56:590-591.
17. Sax KW, Strakowski SM, Keck PE, Upadhyaya VH, **West SA**, McElroy SL: Relationships among negative, positive, and depressive symptoms in schizophrenia and psychotic depression. *Br J Psychiatry* 1996;168:68-71.
18. **West SA**, Sax KW, Stanton SP, Keck PE, McElroy SL, Strakowski SM: Differences in thyroid function studies in acutely manic adolescents with and without ADHD. *Psychopharmacol Bull* 1996;32:63-66.
19. **West SA**, McElroy SL, Keck PE, Strakowski SM: Phenomenology and comorbidity of adolescents hospitalized for the treatment of acute mania. *Biol Psychiatry* 1996; 39:458-460.
20. **West SA**: Medical disorders associated with mania: A review of the literature. *Medical Update for Psychiatrists* 1996;1:28-31.
21. Keck PE, Jr, McElroy SL, Strakowski SM, Balesteri TM, Kizer DL, **West SA**: Factors associated with maintenance antipsychotic treatment of patients with bipolar disorder. *J Clin Psychiatry* 1996;57:147-151.
22. Strakowski SM, McElroy SL, Keck PE, **West SA**: Suicidality in mixed and manic bipolar disorder. *Am J Psychiatry* 1996;153:674-676.
23. McConville BJ, Minnery KL, Sorter MT, **West SA**, Friedman LM, Christian K: An open study of the effects of sertraline on adolescents with major depression. *J Child Adol Psychopharmacol* 1996;6:41-51.
24. Strakowski SM, McElroy SL, Keck PE, **West SA**: The effects of antecedent substance abuse on the development of first- episode psychotic mania. *J Psychiatry Res* 1996;30:59-68.
25. Keck PE, Jr, McElroy SL, Strakowski SM, Stanton SP, Kizer DL, Balesteri TM, Bennett JA, Tugrul KC, **West SA**: Factors associated with pharmacologic noncompliance in

## **SCOTT ALAN WEST, M.D.**

---

- patients with mania. *J Clin Psychiatry* 1996;57:292-297
26. Hall RCW, Cutler A, **West SA**: Bulimia nervosa and diabetes mellitus: A dangerous combination. *Clinical Neuropsychiatry*, 1996.
  27. Strakowski SM, McElroy SL, Keck PE, Jr, **West SA**: Racial influence on diagnosis in psychotic mania. *J Aff Disorders* 1996;39:157-162.
  28. **West SA**, McElroy SL, Keck PE, Jr: Valproate. In: Goodnick PJ ed, *Predictors of Treatment Response in Mood Disorders*. American Psychiatric Press, Inc. 1996, pp 133-146.
  29. McElroy SL, Strakowski SM, **West SA**, Keck PE, McConnville, BJ: Phenomenology of adolescent and adult mania in hospitalized patients with bipolar disorder. *Am J Psychiatry* 1997;154:44-49.
  30. Keck PE, McElroy SL, Strakowski SM, Bourne ML, **West SA**: Compliance with maintenance treatment in bipolar disorder. *Psychopharmacol Bull* 1997;33:87-91.
  31. Sax KW, Strakowski SM, Keck PE, McElroy SL, **West SA**, Bourne ML, Larson ER: A comparison of early-, typical-, and late-onset affective psychosis. *Am J Psychiatry* 1997;154:1299-301.
  32. Strakowski SM, Hawkins JM, Keck PE, McElroy SL, **West SA**, Bourne ML, Sax KW, Tugrul KC: The effects of race and information variance on disagreement between psychiatric emergency service and research diagnoses in first-episode psychosis. *J Clin Psychiatry* 1997;58:457-463.
  33. Baker DG, **West SA**, Orth DN, Hill K, Nicholson W, Ekhaton NN, Bruce A, Wortman M, Keck PE, Jr, Geraciotti TD: Plasma and cerebrospinal fluid beta-endorphin-like immunoreactivity in combat veterans with post traumatic stress disorder. *Psychoneuroendocrinology* 1997;22:517-529.
  34. Arvanitis LA, Miller BG, **Seroquel Study Group**: Multiple fixed doses of seroquel in patients with acute exacerbations of schizophrenia: a comparison with haloperidol and placebo. *Biol Psychiatry* 1997;42:233-46.
  35. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG, **Seroquel Study Group**: Quetiapine in patients with schizophrenia. A high- and low-dose double-blind study with placebo. *Arch Gen Psychiatry* 1997;54:549-57.
  36. Strakowski SM, Keck PE, McElroy SL, **West SA**, Sax KW, et al: Twelve-month

## SCOTT ALAN WEST, M.D.

---

- outcome following a first hospitalization for an affective psychosis. *Arch Gen Psychiatry* 1998;55:49-55.
37. Strakowski SM, Sax KW, McElroy SL, Keck PE, Hawkins JM, **West SA**: Course of psychiatric and substance abuse syndromes co-occurring with bipolar disorder after a first psychiatric hospitalization. *J Clin Psychiatry* 1998;59:465-471.
  38. Block JC, **West SA**, Barharoglu B: Paroxetine treatment of trichotillomania in an adolescent. *J Child Adol Psychopharmacol* 1998;8:69-71.
  39. Sax KW, Strakowski SM, Keck PE, McElroy SL, **West SA**, Stanton SP: Symptom correlates of attentional functioning over acute and compensated states in first-episode psychosis. *Biol Psychiatry* 1998;44:784-786.
  40. Keck PE, McElroy SL, Strakowski SM, **West SA**, Sax KW, Hawkins JM, Bourne ML, Haggard P: Twelve-month outcome of bipolar patients following hospitalization for a manic or mixed episode. *Am J Psychiatry* 1998;155:646-652.
  41. Geraciotti TD, Keck PE, **West SA**, Ekhaton NN, Baker DG, Hill K, Bruce A, Wortman M: Continuous covariability of dopamine and serotonin metabolites in human cerebrospinal fluid. *Biol Psychiatry* 1998;44:228-33.
  42. Baker DG, **West SA**, Nicholson WE, Ekhaton NN, Kasckow JW, Hill KK, Bruce AB, Somoza EC, Orth DN, Geraciotti TD: Serial corticotropin-releasing hormone levels and adrenocortical activity in combat veterans with PTSD. *Am J Psychiatry* 1999;56:585-588.
  43. Geraciotti TD, **West SA**, Baker DG, Hill KK, Ekhaton NN, Keck PE, Norman AB: Low CSF concentration of a dopamine metabolite in tobacco smokers. *Am J Psychiatry* 1999;156:130-132.
  44. DelBello MP, Strakowski SM, Sax KW, McElroy SL, Keck PE, **West SA**, Kmetz GF: The effects of familial rates of affective illness and substance abuse on rates of substance abuse in patients with first-episode mania. *J Affective Disorders* 1999; 56:55-60.
  45. Hill KK, **West SA**, Ekhaton NN, Bruce AB, Wortman MD, Baker DG, Geraciotti TD: The effect of lumbar puncture stress on dopamine and serotonin metabolites in cerebrospinal fluid. *Neurosci Lett* 1999;276:25-8.
  46. Geraciotti TD, Ekhaton NN, **West SA**, Hill KK, Baker DG, Bruce AB, Wortman, Keck PE, Norman AB: Cerebrospinal fluid dopamine and homovanillic acid concentrations in

## **SCOTT ALAN WEST, M.D.**

---

- tobacco smokers and patients with post-traumatic stress disorder. *Arch Gen Psychiatry* 2000.
47. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C, **USA-10 Study Group**: A 5-month, randomized, placebo-controlled trial of galantamine in AD. *Neurology* 2000;54:2269-76.
  48. Calabrese JR, Suppes T, Bowden CL, Sachs GS, Swann AC, McElroy SL, Kusumakar V, Ascher JA, Earl NL, Greene PL, Monaghan E, **Lamictal 614 Study Group**: A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid cycling-bipolar disorder. *J Clin Psychiatry* 2000;61:841-50.
  49. Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG, Sanger T, Risser T, Zhang F, Toma V, Francis J, Tollefson GD, Brier A, **Olanzapine HGGW Study Group**: *Arch Gen Psychiatry* 2000;57:841-9.
  50. Brooks S, Lucey JV, Gunn KP, **Ziprasidone IM Study Group**: Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. *J Clin Psychiatry* 2000;61:93341.
  51. Geraciotti TD, Baker DG, Ekhtor NN, **West SA**, Hill KK, Bruce AB, Schmidt D, Rounds-Kugler B, Yehuda R, Keck PE: Cerebrospinal fluid norepinephrine concentrations in post-traumatic stress disorder. *Am J Psychiatry* 2001;158:1227-1230.
  52. Daniel DG, Potkin SG, Reeves KR, Swift RH, Harrigan EP, **Ziprasidone IM Study Group**: Intramuscular ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. *Psychopharmacology* 2001;155:128-34.
  53. Lessem MD, Zajecka JM, Swift RH, Reeves KR, Harrigan EP, **Ziprasidone IM Study Group**: Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of psychotic patients. *J Clin Psychiatry* 2001;62:12-8.
  54. Keck PE Jr., Reeves KR, Harrigan EP, **Ziprasidone Study Group**: Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies. *J Clin Psychopharmacology* 2001;21:27-35.
  55. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, Spencer T, **Atomoxetine Study Group**: Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled dose-response study. *Pediatrics* 2001;108:e83.

**SCOTT ALAN WEST, M.D.**

---

56. Biederman J, Heiligenstein JH, Faries DE, Galil N, Dittmann R, Emslie GJ, Kratochvil CJ, Laws HF, Schuh KJ, **Atomoxetine ADHD Study Group**: Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder. *Pediatrics* 2002;110:e75.
57. Wagner K, Heiligenstein J, Harder D, Sallee FR, Conner D, Saylor K, Galil N, Newcorn JH, Busner J, Kaplan S, Emslie GJ, **West SA**, Casat CD, Block S, and the Atomoxetine Study Group: Efficacy of atomoxetine in school-age children with the inattentive type of attention-deficit hyperactivity disorder. *J Child Adol Psychopharmacol* 2002.
58. Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, Newcorn J, Sallee FR, Sangal RB, Saylor CK, **West SA**, Kelsey D, Wernicke J, Raute NJ, Harder D: Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. *Am J Psychiatry* 2002;159:1896-1901.
59. Keck PE, Versiani M, Potkin S, **West SA**, Giller E, Ice K: Ziprasidone in the treatment of acute bipolar mania: A three-week, placebo-controlled, double-blind, randomized trial. *Am J Psychiatry* 2003;160:741-748.
60. Michelson D, Adler L, Spencer T, Reimherr FW, **West SA**, Allen AJ, Kelsey D, Wernicke J, Dietrich A, and Milton D: Atomoxetine in adults with ADHD: Two randomized, placebo-controlled studies. *Biol Psychiatry* 2003;53:112-120.
61. Bowden CL, Calabrese JR, Sachs G, Yatham LN, Asghar SA, Homplano M, Montgomery P, Earl N, Smoot TM, DeVeugh-Geiss, **Lamictal 606 Study Group**: A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. *Arch Gen Psychiatry* 2003;60:392-400.
62. Wernicke JF, Adler L, Spencer T, **West S**, Allen AJ, Milton D, Ruff D, Brown WJ, Kelsey D, Michelson D: Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo controlled assessment. *J Clin Psychopharmacology* 2004;24:30-5.
63. Calabrese JR, Casat C, Evoniuk G, Kasper S, Ruetsch G, Shelton M, **West S**, Young T, Zajecka J: Maintenance studies of lamotrigine in bipolar disorder. *Bipolar Disorders*, 2004.
64. Arnold LE, Lindsay RL, Connors CK, Wigal SB, Levine AJ, Johnson DE, **West SA**, Sangal RB, Bohan TP, Zeldis JB: A double-blind, placebo-controlled withdrawal trial of

## **SCOTT ALAN WEST, M.D.**

---

dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder. *J Child Adol Psychopharmacology* 2004;15:2.

65. Kaplan S, Heiligenstein J, **West S**, Busner J, Harder D, Dittman R, Casat C, Brown W. Jeffrey, and Wernicke JF: Efficacy and safety of atomoxetine in childhood attention deficit/hyperactivity disorder with comorbid oppositional defiant disorder. *J Atten Disord* 2004;8:45-52.
66. Reimherr FW, Marchant BK, Strong RE, Hedges DW, Adler L, Spencer TJ, **West SA**, Soni P: Emotional dysregulation in adult ADHD and response to atomoxetine. *Biol Psychiatry* 2005;58:125-31.
67. Calabrese JR, Bowden CL, Sachs G, Yatham LN, Behnke K, et al, and the **Lamictal 605 Study Group**: A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with Bipolar I disorder. *J Clin Psychiatry* 2003;64:1013-24.
68. Wilens TE, Verlinden MH, Adler LA, Wozniak PJ, **West SA**: ABT-089, a neuronal nicotinic modulator, for the treatment of attention deficit hyperactivity disorder in adults: Results of a pilot study. *Biol Psychiatry* 2006;59:1065-1070.
69. Robison RJ, Reimherr FW, Marchant BK, Faraone S, Adler L, Spencer T, **West SA**: Gender differences in a clinical trial of adults with ADHD. *J Clin Psychiatry* 2008;69:213-21.
70. Wilens TE, Klint T, Adler LA, **West SA**, Wesnes K, Graff O, Mikkelsen BO: A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD. *Behav Brain Fucntions* 2008;4:24.

### **Reviews, Book Chapters, & Miscellaneous Publications**

1. **West SA**, Nemeroff CB: Alterations in serotonin neural systems in depression. *Psyche* 1992;1(1):4-10.
2. **West SA**, Nemeroff CB: Atypical antipsychotic drugs; current status and future directions. *Drugs of Today* 1993;29(3):183-188.
3. **West SA**, McElroy SL: Bipolar disorder: Pharmacologic alternatives to lithium. *Employee Assistance* 1993;6(5):17-20.

## **SCOTT ALAN WEST, M.D.**

---

4. **West SA:** Anticonvulsants in the treatment of bipolar disorder. *Psychiatric Times* 1994;11(6):18-20.
5. **West SA, Risch SC:** Non-EPS side effects of typical antipsychotic drugs. In: Shriqui C, Nasrallah HA eds, *Contemporary Issues in the Treatment of Schizophrenia*. American Psychiatric Press, Inc. 1995, pp 575-584.
6. **West SA, McElroy SL, Keck PE, Jr:** Valproate. In: Goodnick PJ ed, *Predictors of Treatment Response in Mood Disorders*. American Psychiatric Press, Inc. 1996, pp 133-146.
7. **West SA:** Adolescent mania and bipolar disorder. *Medscape Mental Health* 2(10), 1997.
8. **West SA:** Child and Adolescent Psychopharmacology. In: Dickstein LJ, Riba MB, Oldham JM eds, *Annual Review of Psychiatry*, Volume 16, American Psychiatric Press, Inc. 1997, Section IV, pp 129-142.
9. **West SA, Keck PE, McElroy SL:** Valproate. In: Goodnick PJ, *Mania: Clinical and Research Perspectives*. American Psychiatric Press, Inc. 1998, pp 301-317.
10. Popper CW, **West SA:** Disorders usually first diagnosed in infancy, childhood, or adolescence. In: Hales RE, Yudofsky SC, Talbott JA eds, *Textbook of Psychiatry*, 3rd Edition, American Psychiatric Press, Inc., 1999, pp 825-954.
11. Popper CW, Gammon GD, **West SA, Bailey CE:** Disorders usually first diagnosed in infancy, childhood, or adolescence. In: Hales RE, Yudofsky SC, Talbott JA eds, *Textbook of Psychiatry*, 4th Edition, American Psychiatric Press, Inc., 2003;833-974.
12. Popper CW, Gammon GD, **West SA, Bailey CE:** Disorders usually first diagnosed in infancy, childhood, or adolescence. In: Hales RE, Yudofsky SC eds, *Essentials of Clinical Psychiatry*, 2<sup>nd</sup> Edition, American Psychiatric Press, Inc. 2004, pp 591-736.
13. Popper CW, Gammon GD, **West SA Bailey CE:** Disorders usually first diagnosed in infancy, childhood, or adolescence. In: Hales RE, Bourgeois J eds, *A Preparation Guide for the ABPN Written Part I Examination*, American Psychiatric Press, Inc. 2006.

### **Selected Research Abstracts**

1. **West SA, Tabb SE:** The forgotten evaluation: taking competence seriously. American Psychiatric Association Annual Convention, San Francisco, CA,

## SCOTT ALAN WEST, M.D.

---

May 1993.

2. **West SA**, McElroy SL, Strakowski SM, Keck, PE, McConville BJ: The comorbidity of ADHD in adolescent mania. American Psychiatric Association Annual Meeting, Philadelphia, PA, May 1994, NR112.
3. Sax KW, Strakowski SM, Keck PE, McElroy SL, **West SA**, Stanton SP: Attention deficit in mixed and pure mania. American Psychiatric Association Annual Meeting, Philadelphia, PA, May 1994, NR111.
4. **West SA**, McElroy SL, Strakowski SM, Keck PE, McConville, BJ: Comorbidity of ADHD in adolescent mania. New Clinical Drug Evaluation Unit Annual Meeting, Marco Island, FL, June 1994; *Psychopharmacology Bull* [abstract].
5. Strakowski SM, Keck PE, McElroy SL, Lonczak HS, Tugrul KL, **West SA**: Chronology of principal and comorbid syndromes in first-episode psychosis. *Biol Psychiatry* [abstract] 35:623-624,1994.
6. Stanton SP, **West SA**, Newman MR, Keck PE, Bennett JA, Tugrul KC: TRH stimulation test in patients with mania, mixed mania, and psychotic depression. International Society of Psychoneuroendocrinology, Seattle, WA, August 1994.
7. Strakowski SM, Keck PE, McElroy SL, Lonczak HS, Tugrul KL, **West SA**: Chronology of principal and comorbid syndromes in first-episode psychosis. Schizophrenia 1994, Vancouver, BC, Canada, August 1994.
8. **West SA**, Strakowski SM, Sax KW: Clinical correlates to hospitalization from a psychiatric emergency room. Hospital and Community Psychiatry Annual Meeting, San Diego, CA, October 1994.
9. Sax KW, Strakowski SM, **West SA**, Lonczak HS, Thienhaus OJ: The effects of race on diagnosis and disposition from a psychiatric emergency room. Institute on Hospital and Community Psychiatry, San Diego, CA, October 1994.
10. Strakowski SM, McElroy SL, Keck PE, **West SA**, Tugrul KL, DePriest M: Racial influence on diagnosis in psychotic mania. Society of Biological Psychiatry, Miami, FL, May 1995.
11. **West SA**, Strakowski SM, Sax KW, Raute NJ, McElroy SL, Keck PE: Phenomenology and comorbidity of adolescents hospitalized for the treatment of acute mania. American Psychiatric Association, Miami, FL, May 1995 (NR148).

**SCOTT ALAN WEST, M.D.**

---

12. Wortman MD, Stanton SP, Keck PE, **West SA**: An indirect measure of dopamine sensitization by serum prolactin levels in humans. American Psychiatric Association, Miami, FL, May 1995 (NR516).
13. **West SA**, Sax KW, Keck PE, Strakowski SM, McElroy SL: Thyroid function studies in acutely manic adolescents with and without ADHD. NCDEU Annual Meeting, Orlando, FL, June 1995. *Psychopharmacol Bull* [abstract].
14. McConville BJ, Minnery KL, Sorter MT, **West SA**, Friedman LM: Sertraline treatment of adolescent depression: An open exploratory study. NCDEU Annual Meeting, Orlando, FL, June 1995. *Psychopharmacol Bull* [abstract].
15. Strakowski SM, Keck PE, McElroy SL, **West SA**: Diagnostic stability of first-episode psychosis. American Psychiatric Association, New York, NY, May 1996. Paper Session (11).
16. Soutullo CA, Chang KD, Stanton SP, Keck PE, McElroy SL, **West SA**: Thyroid function in adolescents with mixed versus pure mania. American Psychiatric Association, New York, NY, May 1996 (NR42).
17. Baker DG, **West SA**, Orth DN, Hill KK, Nicholson WE, Ekhaton NN, Bruce AB, Wortman MD, Keck PE, Geraciotti TD: Cerebrospinal fluid and plasma beta-endorphin in combat veterans with PTSD. *Annals of the NY Academy of Sciences* 1997; 821:449-450 (S212).
18. Geraciotti TD, Ekhaton NN, **West SA**, Hill KK, Baker DG, Bruce AB, Wortman MD, Keck PE, Norman AB: Cerebrospinal fluid dopamine and homovanillic acid concentrations in tobacco smokers and patients with post traumatic stress disorder. *Annals of the NY Academy of Sciences* 1997 (S204).
19. Londborg P, Cutler N, Cunningham L, Haines F, Pahl J, **West S**, Rudd RD: A double-blind, placebo-controlled study supporting the efficacy of lamotrigine in unipolar depression. American Psychiatric Association, Washington, DC, 1999.
20. Suppes T, Cunningham L, Dinan T, Grounds D, Mitchell P, Sokolski K, **West S**, Ascher J, Babiari D, Cedrone J, Laurenza A, Monaghan E: Lamotrigine: Safety data from controlled monotherapy trials in depression. ECNP, London, England, 1999.
21. Ascher J, Babiari D, Cedrone J, Deveaugh\_Geiss J, Londborg P, Pahl J, Shiovitz P, **West S**: A meta analysis of clinical safety data from controlled monotherapy trials of lamotrigine in depression. ACNP, Acapulco, Mexico, December 1999.

**SCOTT ALAN WEST, M.D.**

---

22. Ascher JA, Batey S, Bentley B, Dempsey GM, Kennedy BL, Monaghan ET, **West SA**, Womble GP: A one-year study of lamotrigine in patients with bipolar depression. NCDEU, Boca Raton, FL, May 2000.
23. Keck PE, Ice K, and the **Ziprasidone Study Group**: A three-week, double-blind, randomized trial of ziprasidone in the treatment of acute mania. NCDEU, Boca Raton, FL, May 2000.
24. Conley RR, Mahmoud R, and the **Risperidone Study Group**: Risperidone versus olanzapine in patients with schizophrenia and schizoaffective disorder. NCDEU, Boca Raton, FL, May 2000.
25. Earl N, Greene P, Ascher J, Fouche N, Chang C, Evoniuk G, Swann S, Pope S, Ketter T, McElroy S, Post R, Zajecka J, Altshuler L, Apter J, **West S**, Risch C, Khan A: Mood stabilization with Lamotrigine in rapid cycling bipolar disorder. ECNP, Munich, Germany, September 2000.
26. Ascher J, Barnett S, Batey S, Ketter T, Meredith C, Londborg P, **West S**: Safety and tolerability of lamotrigine in controlled mood disorders trials. APA, New Orleans, LA, May 2001.
27. Heiligenstein J, **West SA**, et al: Tomoxetine in the treatment of ADHD. APA, New Orleans, LA, May 2001.
28. Gyulai L, Suppes T, Apter J, **West S**, Zajecka J, Ascher J, Greene P: Lamotrigine in rapid cycling bipolar disorder: predictors of response. NCDEU, Phoenix, AZ, May 2001.
29. Liebowitz MR, et al, and **Zoloft Social Phobia 601 Study Group**: Results from a randomized, double-blind, multi-center trial of Sertraline in the treatment of moderate-to-severe social phobia (social anxiety disorder). American College of Neuropsychopharmacology (ACNP), Dec 2001.
30. **West SA**, et al: Lithium maintenance treatment in recently depressed patients with bipolar I disorder. American College of Neuropsychopharmacology (ACNP), Waikoloa, HA, Dec 2001.
31. **West SA**, Johnson D, Wigal S, Zeldis J: Withdrawal trial of dex-methylphenidate HCL in children with ADHD. APA, Philadelphia, PA, May 2002.
32. Heiligenstein J, Kaplan S, Harder D, Busner J, **West SA**, Casat CD, Dittmann RW, Wernicke JF: Atomoxetine: clinical outcomes in pediatric ADHD with comorbid ODD.

## **SCOTT ALAN WEST, M.D.**

---

AACAP, San Francisco, CA, October 2002.

33. **West SA**, Johnson D, Wigal SB, Swanson JM, Zeldis JB: Withdrawal trial of dex-methylphenidate HCL (Focalin) in children with ADHD. AACAP, San Francisco, CA, October 2002.
34. Calabrese JR, Casat C, Evoniuk G, Kasper S, Ruetsch G, Shelton M, **West S**, Young T, Zajecka J: Maintenance studies of lamotrigine in bipolar disorder. Anticonvulsants in Psychiatry, Elmau, Germany, April 2003.
35. Reimherr F, Strong RE, Hedges DW, **West SA**, Adler LA, Michelson D, Marchant B: Emotional dysregulation in ADHD and response to atomoxetine. APA, San Francisco, CA, May 2003.
36. **West SA**, Strakowski SM, Keck PE, McElroy SL, Arnold V, McConville BJ: Twelve-Month Outcome of Adolescent Bipolar Patients following Hospitalization for Mania. AACAP, Miami, FL, October 2003.
37. Miller J, Chaney R, Kearney D, Stam M, **West SA**: Recruitment outcomes in child and adolescent depression trials. NCDEU, Phoenix, AZ, June 2004.
38. Spencer T, McGough J, Muniz R, Pestreich L, Kim S, Jiang H, Agoropoulou C, Etropolski M, **Adult ADHD Study Group**: Efficacy of dex-methylphenidate extended-release capsules in adults with ADHD. NCDEU, Phoenix, AZ, June 2004.
39. Emslie G, Wagner KD, Kutcher S, Krulewicz, Caprenter DJ, Lipschitz A, Wilkinson C, **Paroxetine Pediatric MDD 701 Study Group**: Paroxetine treatment in children and adolescents with major depressive disorder. AACAP, Washington, DC, October 2004.
40. **West SA**, Muniz R, Quinn P, Wigal SB, Pestreich L, Wang J: The GRACE Study: An evaluation of girls, Ritalin and ADHD. AACAP, Washington, DC, October 2004.
41. Wilens TE, Verlinden MH, Adler LA, Wozniak PJ, **West SA**: ABT-089, a neuronal nicotinic modulator, for the treatment of attention deficit hyperactivity disorder in adults: Results of a pilot study. AACAP, Toronto, October 2005.
42. Wilens TE, Adler LA, **West SA**, Wesnes K, Mikkelsen BO, Klint T: Efficacy and safety of NS2359 in adults with ADHD. AACAP, San Diego, CA, October 2006.